Neutrophil: lymphocyte ratio and intraoperative use of ketorolac or diflofenac are prognostic factors in breast, lung and kidney cancer surgery

n/

Thrombopoietic effects and toxicity of interleukin-6 in patients with ovarian cancer before and after chemotherapy: a multicentric placebo-controlled, randomized phase Ib study.

Recombinant human interleukin-6 (IL-6) has previously been shown to increase platelet counts in normal and sublethally irradiated mice, dogs, and primates. To assess its tolerance and efficacy in clinical use, we performed a randomized phase Ib study in patients with ovarian carcinoma. IL-6 was administered during an initial 7-day cycle before any chemotherapy. Beginning 7 days later, six cycles of chemotherapy containing carboplatin were administered every 3 weeks. During chemotherapy cycles 2 to 6, IL-6 was administered from day 4 through day 17 at escalating dose levels from 0.5 to 10 micrograms/kg/d. At each level, three patients received IL-6 and one patient received a placebo. During the prechemotherapy cycle of IL-6, a dose-dependent increase in platelet count was observed from day 12 to 15 and was maximal on day 15 (r = .77; P < .01). The median ploidy of bone marrow megakaryocytes shifted from 16 N to 32 N after 7 days of the initial prechemotherapy IL-6 administration. Dose-dependent increases in C-reactive protein (CRP) and fibrinogen levels were observed on day 8 (P < .0001 for both). A significant decrease in hemoglobin level occured rapidly after initiation of IL-6 therapy and was maximal on day 8 (P < .001). When given after chemotherapy, IL-6 accelerated platelet recovery after chemotherapy cycles 2 to 6. Postponements of scheduled chemotherapy due to thrombocytopenia were less frequent in patients treated with IL-6. No difference in either neutrophils or peripheral blood progenitor assays was observed during or after IL-6 treatment. Toxicity of IL-6 appeared mild and was not dose-limiting up to 10 micrograms/kg/d. Systemic symptoms such as fever, headache, and myalgia were the main side effects and were easily relieved by acetaminophen administration. No biologic toxicity was observed. The data indicate that IL-6 is a well-tolerated cytokine and capable of accelerating platelet recovery in patients receiving chemotherapy

Prédication en chapitre général et réforme pontificale de la vita religiosa au XIIIe siècle. À propos des sermons aux chapitres généraux des moines noirs d’Eudes de Châteauroux et Jacques de Furnes

International audienceÀ partir de l’analyse de sermons respectivement donnés par Eudes de Châteauroux et Jacques de Furnes aux chapitres généraux des moines noirs des provinces de Sens et de Reims, l’occasion est offerte de confronter le point de vue de deux acteurs (un gradué séculier ayant la faveur de la papauté et un abbé bénédictin au cœur de la mêlée) sur les réformes monastiques du pape Grégoire IX (1235-1237) et de tenter de cerner les stratégies discursives et les méthodes de gouvernement mises en œuvre par la papauté dans son dessein global de contrôle centralisé de tous les membres de l’Ecclesia. Un sermon de chaque prédicateur est édité en annex